The European Medicines Agency has officially declared testosterone replacement therapy safe from a cardiovascular standpoint, following comprehensive analysis of extended follow-up data from the landmark TRAVERSE trial. This determination represents a significant shift in the regulatory perspective on testosterone therapy, which has faced cardiovascular safety concerns for nearly a decade since earlier observational studies suggested potential risks.
The TRAVERSE trial, which followed over 5,000 middle-aged and older men with hypogonadism for an average of more than three years, found no increased risk of major adverse cardiovascular events among those receiving testosterone therapy compared to placebo. The extended follow-up data that informed the EMA’s decision provides even longer-term safety evidence, addressing one of the most persistent controversies in endocrinology and men’s health. The trial specifically examined rates of heart attack, stroke, and cardiovascular death in men already at elevated cardiovascular risk.
This declaration matters because testosterone prescriptions have faced uncertainty and restrictions across Europe following safety warnings issued in 2014. Many clinicians became hesitant to prescribe testosterone therapy despite its benefits for men with documented hypogonadism, including improved energy, bone density, muscle mass, and sexual function. The regulatory caution stemmed from contradictory observational data and the lack of large-scale randomized controlled trials specifically designed to assess cardiovascular outcomes.
For patients with clinically diagnosed low testosterone, this regulatory determination should facilitate more straightforward access to treatment across European Union member states. Healthcare providers can now prescribe testosterone therapy with greater confidence for appropriate candidates, though the EMA emphasizes that treatment should remain limited to men with confirmed hypogonadism and associated symptoms. The agency’s position aligns treatment decisions with the highest level of clinical evidence, potentially benefiting millions of men who had been caught between symptomatic testosterone deficiency and cardiovascular safety concerns.
